Conflicts — botanical-remedies (round 3)

Conflict: [Cochrane emollients review (van Zuuren), 2017] says oat-containing moisturisers made no significant difference to severity (low quality), with fewer flares but more adverse events (Peto OR 7.26). [Lisante et al., J Dermatolog Treat, 2017] says 1% oatmeal cream was non-inferior to prescription barrier cream in 90 children with “no safety issues”. [AAP, n.d.] says oatmeal baths improve AD symptoms incl. itch in children. Unresolved — add to open_questions. Note: Colloidal Oatmeal

Conflict: [Boussault et al., Allergy, 2007] suggests avoiding topical oat-protein products in infants with AD (oat APT+ in 32% of oat-cream users vs 0% of non-users). [Lisante et al., 2017; FDA OTC Skin Protectant monograph] treat 1% colloidal oatmeal as safe in children from 6 months. Unresolved — add to open_questions. Note: Colloidal Oatmeal

Conflict: [Patzelt-Wenczler & Ponce-Pöschl, Eur J Med Res, 2000] says the Manzana chamomile in Kamillosan “has been proved not to exhibit a chamomile-related allergen potential”. [DermNet NZ, n.d.] says the proprietary chamomile cream “has also been reported to cause allergic dermatitis on a number of occasions” (Rudzki 1998, positive patch test with Kamillosan). Unresolved — add to open_questions. Note: Chamomile